VAUGHAN & Co SECURITIES INC. bought a new position in shares of CVS Health Corporation (NYSE:CVS - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 13,271 shares of the pharmacy operator's stock, valued at approximately $899,000. CVS Health comprises 0.6% of VAUGHAN & Co SECURITIES INC.'s holdings, making the stock its 19th largest holding.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Norges Bank bought a new position in shares of CVS Health during the 4th quarter valued at about $839,574,000. Capital World Investors lifted its holdings in shares of CVS Health by 26.6% during the 4th quarter. Capital World Investors now owns 61,039,777 shares of the pharmacy operator's stock valued at $2,739,927,000 after purchasing an additional 12,819,148 shares in the last quarter. Davis Selected Advisers lifted its holdings in shares of CVS Health by 2,998.1% during the 4th quarter. Davis Selected Advisers now owns 11,385,950 shares of the pharmacy operator's stock valued at $511,115,000 after purchasing an additional 11,018,438 shares in the last quarter. Dodge & Cox lifted its holdings in shares of CVS Health by 11.2% during the 4th quarter. Dodge & Cox now owns 70,105,899 shares of the pharmacy operator's stock valued at $3,147,054,000 after purchasing an additional 7,075,209 shares in the last quarter. Finally, Pzena Investment Management LLC lifted its holdings in shares of CVS Health by 49.3% during the 4th quarter. Pzena Investment Management LLC now owns 19,610,579 shares of the pharmacy operator's stock valued at $880,319,000 after purchasing an additional 6,475,271 shares in the last quarter. Institutional investors own 80.66% of the company's stock.
Analysts Set New Price Targets
Several equities analysts have recently weighed in on the company. Morgan Stanley reiterated an "overweight" rating on shares of CVS Health in a report on Tuesday, April 15th. Barclays set a $79.00 target price on CVS Health and gave the company an "overweight" rating in a research note on Monday, June 2nd. Truist Financial boosted their target price on CVS Health from $82.00 to $84.00 and gave the company a "buy" rating in a research note on Monday, May 12th. Cowen restated a "buy" rating on shares of CVS Health in a research note on Monday, May 5th. Finally, Robert W. Baird boosted their price target on CVS Health from $51.00 to $71.00 and gave the stock a "neutral" rating in a research report on Tuesday, April 15th. Two investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $75.06.
Read Our Latest Report on CVS
CVS Health Price Performance
Shares of CVS stock traded up $0.78 on Friday, hitting $67.38. 3,770,987 shares of the company's stock were exchanged, compared to its average volume of 10,851,185. The company has a debt-to-equity ratio of 0.77, a current ratio of 0.82 and a quick ratio of 0.63. CVS Health Corporation has a 12 month low of $43.56 and a 12 month high of $72.51. The stock has a market cap of $85.23 billion, a P/E ratio of 16.08, a price-to-earnings-growth ratio of 0.97 and a beta of 0.57. The company has a 50 day moving average of $65.11 and a 200 day moving average of $61.71.
CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.63. CVS Health had a return on equity of 10.59% and a net margin of 1.39%. The business had revenue of $94.59 billion during the quarter, compared to the consensus estimate of $93.07 billion. During the same period in the prior year, the company earned $1.31 EPS. CVS Health's revenue for the quarter was up 7.0% on a year-over-year basis. On average, equities research analysts predict that CVS Health Corporation will post 5.89 EPS for the current year.
Insider Transactions at CVS Health
In other news, Director Guy P. Sansone bought 1,570 shares of the stock in a transaction on Thursday, June 5th. The stock was acquired at an average price of $63.70 per share, with a total value of $100,009.00. Following the acquisition, the director directly owned 12,007 shares in the company, valued at approximately $764,845.90. This trade represents a 15.04% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.22% of the stock is currently owned by insiders.
About CVS Health
(
Free Report)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
See Also

Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.